Cite
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
MLA
Jerusalem, G., et al. “Continuous versus Intermittent Extended Adjuvant Letrozole for Breast Cancer: Final Results of Randomized Phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 32, no. 10, Oct. 2021, pp. 1256–66. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.07.017.
APA
Jerusalem, G., Farah, S., Courtois, A., Chirgwin, J., Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O’Reilly, S., … Colleoni, M. (2021). Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 32(10), 1256–1266. https://doi.org/10.1016/j.annonc.2021.07.017
Chicago
Jerusalem, G, S Farah, A Courtois, J Chirgwin, S Aebi, P Karlsson, P Neven, et al. 2021. “Continuous versus Intermittent Extended Adjuvant Letrozole for Breast Cancer: Final Results of Randomized Phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 32 (10): 1256–66. doi:10.1016/j.annonc.2021.07.017.